Advance in pharmacological effects of sirolimus

SU Feng-yun; LIU Ai-jun; SU Ding-feng

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Sirolimus, a kind of macrolide antibiotics, was widely used in clinical as immunosuppressive agents. In recently research, it had been found that sirolimus had potent biologic activities in terms of anti-inflammatory, immunosuppression, anti-neoplasms, anti-atherosclerosis, anti-aging, neuroprotection and so on. The progress pharmacological effects in the past ten years and forecaesd and the development prospects of sirolimus were reviewed in this paper.

Advance in pharmacological effects of sirolimus

Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2011-02-28

Rev Recd Date: 2011-06-29

Key words:

Abstract: Sirolimus, a kind of macrolide antibiotics, was widely used in clinical as immunosuppressive agents. In recently research, it had been found that sirolimus had potent biologic activities in terms of anti-inflammatory, immunosuppression, anti-neoplasms, anti-atherosclerosis, anti-aging, neuroprotection and so on. The progress pharmacological effects in the past ten years and forecaesd and the development prospects of sirolimus were reviewed in this paper.

HTML

Reference (27)

[1]	Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice[J]. Nature, 2009,460(7253):392.
[2]	Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease[J]. PLoS One, 2010,5(4):e9979.
[3]	Zhai XZ, Yao YM, Wang SH, et al. Activation of signal transducer and activator of transcription 3 in multiple organs of rats with sepsis[J]. Chin J Trauma, 2004,20(3):146.
[4]	姚胜,姚咏明,李红云,等. 雷帕霉素对烫伤后金黄色葡萄球菌脓毒症大鼠白细胞介素[J].中华急诊医学杂志,2006,15(1):34.
[5]	Krakauer T, Buckley M, Issaq HJ, et al. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo[J]. Antimicrob Agents Chemother, 2010,54(3):1125.
[6]	Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic[J]. Curr Opinion Invest Drugs, 2002,3(2):295.
[7]	Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis[J]. Adv Cancer Res, 2009,102:19.
[8]	Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer [J]. Gut Liver, 2010,4(4):433.
[9]	Sedrani R, Cotterns S, Kallen J. Chemical modification of rapamycin: the discovery of SDZ RAD[J]. Transplant Proc,1998,30(5):2192.
[10]	Merimsky O, Jiveliouk I, Sagi-Eisenberg R. Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma[J]. Sarcoma, 2008,2008:825093.
[11]	Tsai MK, Wu FL, Lai IR, et al. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy[J]. Int J Artif Organs, 2009, 32(6):371.
[12]	张全胜, 史瑞, 刘懿禾. 肝移植术后西罗莫司致间质性肺炎[J]. 中国危重病急救医学, 2010, 7:436.
[13]	Josep MC. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors[J]. Transplant Rev, 2008,22(1):73.
[14]	Fukuda D, Sata M, Tanaka K, et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells[J]. Circulation, 2005,111(7):926.
[15]	Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial[J]. Eur Heart J, 2007,28(16):1946.
[16]	Ma KL, Ruan XZ, Powis SH, et al. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells[J]. Am J Physiol Heart Circ Physiol, 2007,292(6):H2721.
[17]	Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy[J]. Annu Rev Pharmacol Toxicol, 2007,47:443.
[18]	Kuzman JA, OConnell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy[J]. Endocrinology, 2007,148(7):3477.
[19]	Soesanto W, Lin HY, Hu E, et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats[J]. Hypertension,2009,54(6):1321.
[20]	Steiner JP, Connolly MA, Valentine HL, et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporine A[J]. Nat med ,1997,3(4):421.
[21]	Ruan B, Pong K, Jow F, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activitie[J]. Proc Natl Acad Sci USA, 2008,105(1):33.
[22]	Qi H, Chen Y, Fu X, et al. TOR regulates cell death induced by telomere dysfunction in budding yeast[J]. PLoS One, 2008,3(10):e3520.
[23]	Liu S, Lu B. Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster[J]. PLoS Genet, 2010,6(12):e1001237.
[24]	Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster[J]. Cell Metab, 2010,11(1):35.
[25]	Malagelada C, Jin ZH, Jackson-Lewis V, et al. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease[J]. J Neurosci, 2010,30(3):1166.
[26]	Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporineand prednisone-dependent myasthenia gravis[J]. Neurology, 2005,64(9):1641.
[27]	Phornphutkul C, Lee M, Voigt C, et al. The effect of rapamycin on bone growth in rabbits[J]. J Orthop Res, 2009,27(9):1157.

Message Board

Advance in pharmacological effects of sirolimus

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views